ArticleNorthern clinics of Istanbul2026
The effect of cytoreductive nephrectomy on survival in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors.
Article in Northern clinics of Istanbul, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (RCC) is controversial. The aim of this study was to compare survival outcomes between nephrectomy and non-nephrectomy groups in patients with de novo metastatic renal cell carcinoma receiving tyrosine kinase inhibitors (TKI).
methodsThis retrospective study included 99 patients with de novo metastatic renal cell carcinoma, stratified according to receipt of cytoreductive nephrectomy. Baseline clinicopathological variables, including International Metastatic RCC Database Consortium (IMDC) risk category, Eastern Cooperative Oncology Group (ECOG) performance status, sarcomatoid features, Fuhrman grade, and TKI regimen, were collected. Overall survival was evaluated using Kaplan-Meier analysis.
resultsAmong 99 patients, IMDC risk categories were favorable in 21 (21.2%), intermediate in 52 (52.5%), and poor in 26 (26.3%). CN was performed in 67 patients (67.7%). Pazopanib and sunitinib were used in 50 (50.5%) and 49 (49.5%) patients, respectively. In comparison with the nephrectomy cohort, a greater percentage of patients in the non-nephrectomy cohort were classified as poor risk (37.5% vs. 20.8%, p=0.010). Overall survival differed significantly across IMDC risk groups (p=0.001). In the favorable-risk subgroup, median overall survival was longer with nephrectomy than without surgery (42 vs. 12 months, p=0.042). There was no significant difference in survival between pazopanib and sunitinib treatment (14 vs. 16 months, p=0.251).
conclusionCN was associated with improved overall survival in the favorable-risk subgroup, whereas no significant survival difference was observed in intermediate- or poor-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.